[Long-term therapy of hypercholesteremia in diabetics with colestipol].
64 hypercholesterolemic diabetics (17 males and 47 females) were treated with Colestipol for 3 years. An average reduction of 29% in serum cholesterol levels was observed after 3 years. An increase in triglyceride levels was observed in several instances. Other laboratory data failed to reveal any deviation from normal ranges. Gastrointestinal complaints and constipation were initially noted with onset of therapy. These side effects resolved with continuation of treatment.
D000368:Aged; D002784:Cholesterol / Q000097:blood; D003084:Colestipol / Q000627:therapeutic use*; D003920:Diabetes Mellitus / Q000097:blood*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D011073:Polyamines; D014280:Triglycerides; D002784:Cholesterol; D003084:Colestipol
Langzeittherapie der Hypercholesterinämie beim Diabetiker mit Colestipol.